Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591173 · ClinicalTrials.gov registry record · Early Phase 1
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
A Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02591173 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT02591173, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models. There are limited and contradictory clinical studies, however, and it is not clear if this peptide regulates blood pressure in humans. The purpose of this study is to better understand the cardiovascular effects angiotensin-(1-7) in human hypertension, and to examine interactions of this peptide with the autonomic nervous system. The investigators propose that the difficulties in showing angiotensin-(1-7) cardiovascular effects in previous clinical studies relates to the buffering capacity of the baroreceptor reflex to prevent changes in blood pressure. Autonomic failure provides the ideal patient population to test this hypothesis. These patients have loss of baroreflex buffering and have low levels of angiotensin-(1-7) in blood. The investigators will test if angiotensin-(1-7) infusion can lower blood pressure in patients with autonomic failure, and will determine the hemodynamic and hormonal mechanisms involved in this effect.
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02591173
The ClinicalTrials.gov registry entry for NCT02591173 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02591173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02591173 about?
NCT02591173 is a clinical study titled "Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure". Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models. There are limited and contradictory clinical studies, however, and it is not clear if this peptide...
What is the current status of trial NCT02591173?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2016-02. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02591173?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT02591173?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.